title: Chimerism versus minimal residual disease monitoring after allogeneic transplantation--when do we act and will intervention improve outcomes?
authors: Division of Hematology and Hematological Malignancies, Huntsman Cancer Institute/University of Utah School of Medicine, Primary Children's Hospital, Salt Lake City, Utah. Electronic address: michael.pulsipher@hsc.utah.edu.
authors: Michael A
authors: MA
authors: Pulsipher
mesh_terms: D001853:Bone Marrow / Q000378:metabolism / Q000473:pathology; D015870:Gene Expression; D006086:Graft vs Host Disease / Q000517:prevention & control; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007136:Immunoglobulins / Q000235:genetics; D000922:Immunotoxins / Q000627:therapeutic use*; D018365:Neoplasm, Residual; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000235:genetics / Q000276:immunology / Q000401:mortality / Q000628:therapy*; D011379:Prognosis; D012008:Recurrence; D012307:Risk Factors; D016019:Survival Analysis; D018183:Transplantation Chimera / Q000235:genetics / Q000276:immunology*; D014184:Transplantation, Homologous; D016896:Treatment Outcome
chemical_list: D007136:Immunoglobulins; D000922:Immunotoxins